Rosuvastatin

This classification denotes a hmg-coa reductase inhibitor with the molecular formula C22H28FN3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 413KH5ZJ73, chemically known as (3r,5s,6e)-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid but generally known as rosuvastatin, which bears US NIH Compound Identifier 446157. European Medicines Agency schedules Rosuvastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20634. The term ROSUVASTATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 1, 2001, List 45). World Health Organization schedules rosuvastatin in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule rosuvastatin under HS 29350090 and SITC 51580. As of Q4 2014, ROSUVASTATIN remains the US FDA Preferred Term for this commodity. Rosuvastatin bears US NLM identifiers UMLS ID C0965129 and NCI Concept Code C66523. SMILES: S(=O)(=O)(N(c1nc(C(C)C)c(c(n1)c1ccc(F)cc1)/C=C/C(O)CC(O)CC(=O)O)C)C.